Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer

Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer

Submitted by admin on August 21, 2023 - 10:02am
Source: 
Clinical Trials Arena
News Tags: 
Exelixis
Ipsen
Carbometyx
prostate cancer
Headline: 
Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer
snippet: 

The Phase III trial for the Cabometyx and Tecentriq combination treatment met progression-free survival endpoint in metastatic prostate cancer.

Do Not Allow Advertisers to Use My Personal information